Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Sensus Healthcare has a “Moderate Buy” consensus rating from six analysts: four buys, one hold, and one sell. The average 12-month price target is $5.83, compared with the stock’s recent price of $3.12.
• The company reported weak quarterly results, with a $0.53 loss per share versus the $0.12 expected loss and revenue of $2.29 million versus the $4.60 million estimate.
• Insiders have recently increased their holdings, acquiring 120,171 shares over 90 days, while institutional investors own 25.3% of the stock.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $5.8333.

A number of equities analysts recently weighed in on the company. Weiss Ratings cut Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. Alliance Global Partners restated a "buy" rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Lake Street Capital decreased their target price on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating on the stock in a research report on Friday, August 14th.

Sensus Healthcare Stock Performance

SRTS stock opened at $3.12 on Friday. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49. The firm's fifty day moving average is $3.11 and its 200 day moving average is $3.43. The firm has a market cap of $51.36 million, a PE ratio of -3.32 and a beta of 1.13.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million.

Insiders Place Their Bets

In related news, Director Eric Sachetta acquired 37,537 shares of the firm's stock in a transaction on Friday, August 28th. The shares were acquired at an average cost of $3.44 per share, with a total value of $129,127.28. Following the completion of the acquisition, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This trade represents a 16.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 120,171 shares of company stock worth $405,230 in the last ninety days. Corporate insiders own 10.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Sensus Healthcare in the second quarter valued at approximately $252,000. Bank of New York Mellon Corp purchased a new position in Sensus Healthcare in the 2nd quarter valued at $303,000. EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare during the 2nd quarter worth $49,000. Finally, North Star Investment Management Corp. purchased a new stake in shares of Sensus Healthcare during the first quarter worth $500,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical device company focused on noninvasive treatments for dermatologic and oncologic conditions. The company develops and commercializes superficial radiation therapy systems designed to deliver low-energy X-rays to targeted areas of the skin while limiting exposure to surrounding tissue.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used primarily to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as certain keloid scars.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.